Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Antonio, Cusmai"'
Autor:
Antonello Pinto, Chiara Guarini, Marianna Giampaglia, Valeria Sanna, Assunta Melaccio, Laura Lanotte, Anna Natalizia Santoro, Francesca Pini, Antonio Cusmai, Francesco Giuliani, Gennaro Gadaleta-Caldarola, Palma Fedele
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1146 (2024)
The advent of immunotherapy and antibody–drug conjugates (ADCs) have revolutionized breast cancer treatment, offering new hope to patients. However, challenges, such as resistance and limited efficacy in certain cases, remain. Recently, the combina
Externí odkaz:
https://doaj.org/article/7a271d13ab684c7ca0b0fb20eae97d14
Autor:
Gennaro Gadaleta-Caldarola, Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, Arianna Gadaleta-Caldarola, Stefania Infusino, Antonio Cusmai, Claudia Citrigno, Gennaro Palmiotti
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7925-7931 (2022)
Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemig
Externí odkaz:
https://doaj.org/article/4fa626ba992f49b19c039aaaba1e5f5f
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
Autor:
Alessandro Rizzo, Angela Dalia Ricci, Antonio Cusmai, Silvana Acquafredda, Giuseppe De Palma, Giovanni Brandi, Gennaro Palmiotti
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 551-564 (2022)
Recent years have seen some breakthroughs in the therapeutic landscape of advanced biliary tract cancer (BTC). Firstly, a better understanding of the molecular background of BTC has led to important improvements in the management of these hepatobilia
Externí odkaz:
https://doaj.org/article/4a27d1ea4b4a4df0a1bf3d8ba5993a70
Autor:
Gennaro Gadaleta-Caldarola, Laura Lanotte, Stefania Infusino, Arianna Gadaleta-Caldarola, Francesca Matilde Schipilliti, Claudia Citrigno, Cataldo Petrarota, Antonio Cusmai, Alessandro Rizzo
Publikováno v:
Cancer Treatment and Research Communications, Vol 37, Iss , Pp 100775- (2023)
Background: TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd). Research design and methods: Herein, we
Externí odkaz:
https://doaj.org/article/d4e1879ceb08478b8f850e8b44cd69ae
Autor:
Alessandro Rizzo MD, Antonio Cusmai MD, Raffaella Massafra PhD, Samantha Bove PhD, Maria Colomba Comes PhD, Annarita Fanizzi PhD, Gennaro Gadaleta-Caldarola MD, Donato Oreste MD, Alfredo Zito MD, Francesco Giotta MD, Vito Lorusso MD, Gennaro Palmiotti MD
Publikováno v:
Cancer Control, Vol 29 (2022)
Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2
Externí odkaz:
https://doaj.org/article/360c03889f5c4df8bfe1bc8d24c80f02
Autor:
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Publikováno v:
Cells, Vol 11, Iss 12, p 1857 (2022)
Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant
Externí odkaz:
https://doaj.org/article/1d10e54901184395b763dfcdee2f06db
Publikováno v:
Medicina, Vol 58, Iss 5, p 600 (2022)
Immunotherapy has revolutionized previous triple-negative breast cancer (TNBC) treatment algorithms, prompting researchers and clinicians to consider the expansion of the role of immunotherapy in other settings, including the earlier stage of the dis
Externí odkaz:
https://doaj.org/article/710760f412234130b69dfa9dcd1ba341
Autor:
Alessandro, Rizzo, Riccardo, Carloni, Angela Dalia, Ricci, Antonio, Cusmai, Mariarita, Laforgia, Concetta, Calabrò, Valentina, Ungaro, Donato, Oreste, Mario, Sollitto, Gennaro, Palmiotti, Giovanni, Brandi
Publikováno v:
Expert Opinion on Drug Safety. 22:323-329
Despite all the improvements achieved over the last decade, the use of immune checkpoint inhibitors (ICIs) has been associated to a wide range of adverse drug events, which are frequently markedly different from those observed with cytotoxic chemothe
Autor:
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Davide Bimbatti, Franco Nolè, Francesco Carrozza, Sebastiano Buti, Roberto Iacovelli, Chiara Ciccarese, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scagliarini, Sandro Pignata, Filippo de Braud, Elena Verzoni
Publikováno v:
Tumori Journal. 109:129-137
Background: First-line therapies based on immune-checkpoint inhibitors (ICIs) significantly improved survival of metastatic renal cell carcinoma (mRCC) patients. Cabozantinib was shown to target kinases involved in immune-escape and to prolong surviv
Autor:
Riccardo Carloni, Alessandro Rizzo, Antonio Cusmai, Andrea Palloni, Alessandro Di Federico, Mariacristina Di Marco, Raffaella Massafra, Annarita Fanizzi, Gennaro Palmiotti, Giovanni Brandi
Publikováno v:
Future Medicinal Chemistry. 14:1455-1470
Hepatocellular carcinoma (HCC) represents the most frequent type of primary liver tumor. Most HCC patients present with advanced disease at diagnosis and the recurrence rate after surgery remains high. Treatment options for advanced HCC are limited,